Concert Pharmaceuticals to Webcast Presentation at UBS Virtual Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, May 12, 2020
Information
Tags: 
Health, Infectious diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Life sciences, Articles, Health, Pharmaceutical industry, Specialty drugs, Biopharmaceutical, Biotechnology, Pharmacy, Pharmaceutical industry in China, Medication
Geotags: 
Massachusetts, United States
⚠ generated by AI ↴
Organisation: 
CONCERT
Summary
Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m.
  • A live webcast of the presentation may be accessed in the Investors section of the Companys website at www.concertpharma.com .
  • A replay of the webcast will be available on Concerts website for two weeks following the presentation.
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.


Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET.

A live webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Copyright: 
Copyright Business Wire 2020